Dr. Sam Benjamin, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 24
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 426
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 003896
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University Hospital S U N Y Health Science Center Syracuse, NY
- Wynn Hospital Utica, NY
- Oswego Hospital Oswego, NY
- Oneida Health Hospital Oneida, NY
- Auburn Community Hospital Auburn, NY
Medical groups
- Department of Medicine Medical Serv Grp at Suny Hlth Sci Ctr Syr in (282 clinicians)
- Auburn Community Hospital (60 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 426
- Services billed
- 1,125
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 1,920 | 14 |
| Established patient office or other outpatient visit, 30-39 minutes | 753 | 329 |
| Established patient office or other outpatient visit, 40-54 minutes | 206 | 150 |
| Administration of chemotherapy into vein, 1 hour or less | 108 | 19 |
| New patient office or other outpatient visit, 60-74 minutes | 74 | 74 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 52 | 18 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 24 | 22 |
| Injection of drug or substance under skin or into muscle | 23 | 16 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 21 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Syracuse, NY | 349 |
| Prochlorperazine Maleate Other prescribers in Syracuse, NY | 39 |
| Prednisone Other prescribers in Syracuse, NY | 37 |
| Tamoxifen Citrate Other prescribers in Syracuse, NY | 33 |
| Ondansetron Hcl Other prescribers in Syracuse, NY | 33 |
| Abiraterone Acetate | 27 |
| Exemestane | 22 |
| Dexamethasone Other prescribers in Syracuse, NY | 19 |
| Letrozole Other prescribers in Syracuse, NY | 17 |
| Duloxetine Hcl Other prescribers in Syracuse, NY | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 11 payments worth $243 in total to this clinician.
| Pfizer Inc. | $76.23 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $48.96 |
| Novartis Pharmaceuticals Corporation | $41.67 |
| AbbVie Inc. | $33.76 |
| AstraZeneca Pharmaceuticals LP | $23.83 |
| Genentech USA, Inc. | $19.02 |
| Food and Beverage | $243 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $127,806 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell…
Exelixis Inc. - A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054 - An interventional openlabel randomized multicenter phase 3 study of PF07220060 plus fulvestrant compared to investigators choice of therapy in participants over 18 years of age with hormone receptorpositive HER2NEG…
Pfizer Inc. - A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Exelixis Inc. - Chemo trastuzumab vs chemo trastuzumab pertuzumab
Genentech, Inc. - Pallaspalbociclib collaborative adjuvant studya randomized phase iii trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hr or HER2 early breast cancer WI…
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.